Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors [Seeking Alpha]
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Seeking Alpha
28min Summary In my previous article, I rated Ocular as a “Hold” based on concerns regarding Axpaxli's path to market. The SOL-1 and SOL-R Phase III trials are designed to assess Axpaxli's safety, efficacy, and potential market disruption in wet-AMD treatment. OCUL's Elutyx drug delivery platform offers sustained long-term effects, making it a valuable asset beyond current retina-focused applications. Despite financial losses, Ocular's strong cash position and strategic focus on Axpaxli support a stable outlook until potential commercialization in 2026-2027. Macular degeneration is a medical condition which may result in blurred or no vision in the center of the visual field. Tunatura/iStock via Getty Images Thesis In my previous article focused on Ocular Therapeutix ( NASDAQ: OCUL ), I rated the This article was written by BioCGT Investor Follower s Follow Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual MeetingGlobeNewswire
- Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDRGlobeNewswire
OCUL
Earnings
- 11/14/24 - Beat
OCUL
Analyst Actions
- 12/3/24 - HC Wainwright
OCUL
Sec Filings
- 2/14/25 - Form 8-K
- 2/14/25 - Form SCHEDULE
- 2/13/25 - Form 4
- OCUL's page on the SEC website